中国KYM Biosciences:收到4500万美金MNC药企付款

药融圈
Mar 11

药融圈监测显示:中国药企KYM Biosciences Inc.于2023年2年与 阿斯利康 AstraZeneca订立全球独家许可协议,授权AstraZeneca在全球范围开发及商业化CMG901。基于当时的许可协议,KYM将获得6300万美元预付款和超过11亿美元的潜在额外开发和销售相关里程碑付款。目前,AstraZeneca已就AZD0901治疗晚期实体瘤开展了多项全球临床研究,适应症含括...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10